The elevated gene expression level of the A2B adenosine receptor is associated with hyperglycemia in women with gestational diabetes mellitus

Diabetes/Metabolism Research and Reviews

Volumn 30, Issue 1, 2014, Pages 42-53

  Wojcik, Marzena ^a   Zieleniak, Andrzej ^a   Mac Marcjanek, Katarzyna ^a   Wozniak, Lucyna A ^a   Cypryk, Katarzyna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Adenosine receptor; Gestational diabetes mellitus (GDM); Insulin resistance; Type 2 diabetes mellitus (T2DM)

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; MESSENGER RNA;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; LEUKOCYTE; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; ORAL GLUCOSE TOLERANCE TEST; POLYMERASE CHAIN REACTION; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOSINE RECEPTOR; GESTATIONAL DIABETES MELLITUS (GDM); INSULIN RESISTANCE; TYPE 2 DIABETES MELLITUS (T2DM);

ADULT; BLOOD GLUCOSE; DIABETES, GESTATIONAL; FEMALE; GENE EXPRESSION; HUMANS; HYPERGLYCEMIA; LEUKOCYTES; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY TRIMESTER, THIRD; RECEPTOR, ADENOSINE A2B; RNA, MESSENGER;

EID: 84892473155     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2446     Document Type: Article

References (64)

1. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2003; 26: S103-S105.
2. Schmidt MI, Duncan BB, Reichelt AJ, et al. Brazilian Gestational Diabetes Study Group. Gestational diabetes mellitus diagnosed with a 2-h 75-g oral glucose tolerance test and adverse pregnancy outcomes. Diabetes Care 2001; 24: 1151-1155.
3. Gilmartin AB, Ural SH, Repke JT. Gestational diabetes mellitus. Rev Obstet Gynecol 2008; 1: 129-134.
4. Buchanan TA. Pancreatic B-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 989-993.
5. Carr DB, Utzschneider KM, Hull RL, et al. Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of type 2 diabetes. Diabetes Care 2006; 29: 2078-2083.
6. Metzger BE. Long-term outcomes in mothers diagnosed with gestational diabetes mellitus and their offspring. Clin Obstet Gynecol 2007; 50: 972-979.
7. Buchanan TA, Xiang A, Kjos SL, Watanabe R. What is gestational diabetes? Diabetes Care 2007; 30: S105-S111.
8. Kautzky-Willer A, Pacini G, Tura A, et al. Increased plasma leptin in gestational diabetes. Diabetologia 2001; 44: 164-172.
9. Winkler G, Cseh K, Baranyi E, et al. Tumor necrosis factor system and insulin resistance in gestational diabetes. Diabetes Res Clin Pract 2002; 56: 93-99.
10. Retnakaran R, Hanley AJ, Raif N, Connelly PW, Sermer M, Zinman B. C-reactive protein and gestational diabetes: the central role of maternal obesity. J Clin Endocrinol Metab 2003; 88: 3507-3512.
11. Retnakaran R, Hanley AJ, Raif N, Connelly PW, Sermer M, Zinman B. Reduced adiponectin concentration in women with gestational diabetes: a potential factor in progression to type 2 diabetes. Diabetes Care 2004; 27: 799-800.
12. Colomiere M, Permezel M, Lappas M. Diabetes and obesity during pregnancy alter insulin signalling and glucose transporter expression in maternal skeletal muscle and subcutaneous adipose tissue. J Mol Endocrinol 2010; 44: 213-223.
13. Lappas M, Hiden U, Froehlich J, Desoye G, Haugel-de Mouzon S, Jawerbaum A. The role of oxidative stress in the pathophysiology of gestational diabetes mellitus. Antioxid Redox Signal 2011; 15: 3061-3100.
14. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53: 527-552.
15. 1 adenosine receptors in diabetes treatment. Curr Pharm Des 2010; 16: 4237-4242.
16. Grden M, Podgorska M, Szutowicz A, Pawelczyk T. Diabetes-induced alterations of adenosine receptors expression level in rat liver. Exp Mol Pathol 2007; 83: 392-398.
17. Grden M, Podgorska M, Szutowicz A, Pawelczyk T. Altered expression of adenosine receptors in heart of diabetic rat. J Physiol Pharmacol 2005; 56: 587-597.
18. Pawelczyk T, Grden M, Rzepko R, Sakowicz M, Szutowicz A. Region-specific alterations of adenosine receptors expression level in kidney of diabetic rat. Am J Pathol 2005; 167: 315-325.
19. Gokulakrishnan K, Mohanavalli KT, Monickaraj F, Mohan V, Balasubramanyam M. Subclinical inflammation/oxidation as revealed by altered gene expression profiles in subjects with impaired glucose tolerance and type 2 diabetes patients. Mol Cell Biochem 2009; 324: 173-181.
20. Hatanaka E, Monteagudo PT, Marrocos MS, Campa A. Neutrophils and monocytes as potentially important sources of proinflammatory cytokines in diabetes. Clin Exp Immunol 2006; 146: 443-447.
21. Shurtz-Swirski R, Sela S, Herskovits AT, et al. Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetic patients. Diabetes Care 2001; 24: 104-110.
22. Tong PC, Lee KF, So WY, et al. White blood cell count is associated with macro- and microvascular complications in Chinese patients with type 2 diabetes. Diabetes Care 2004; 27: 216-222.
23. Linden J. Regulation of leukocyte function by adenosine receptors. Adv Pharmacol 2011; 61: 95-114.
24. Yang D, Zhang Y, Nguyen HG, et al. The A2b adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest 2006; 116: 1913-1923.
25. Figler RA, Wang G, Srinivasan S, et al. Links between insulin resistance, adenosine A2B receptors, and inflammatory markers in mice and humans. Diabetes 2011; 60: 669-679.
26. Zieleniak A, Cypryk K, Wozniak LA, Bieńkiewicz M, Wójcik M. Adenosine receptors expression is elevated in leukocytes of gestational diabetes mellitus (GDM) subjects - a preliminary study. Endokrynol Pol 2012; 63: 110-114.
27. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of WHO/IDF consultation. World Health Organization and International Diabetes Federation. WHO Document Production Services Geneva Switzerland, 2006.
28. Jacobs NJ, VanDenmark PJ. Enzymatic determination of serum triglyceride.ch. Biochem Biophys 1960; 88: 250-255.
29. Allain CC, Poon IS, Chan CHG, Richmond W, Fu PC. Enzymatic determination of serum total cholesterol. Clin Chem 1974; 20: 470-471.
30. Metus P, Ruzzante N, Bonvicini P, Meneghetti M, Zaninotto M, Plebani M. Immunoturbidimetric assay of glycated hemoglobin. J Clin Lab Anal 1999; 13: 5-8.
31. Eda S, Kaufmann J, Roos W, Pohl S. Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range. J Clin Lab Anal 1998; 12: 137-144.
32. Sapin R, Le Galudec V, Gasser F, Pinget M, Grucker D. Elecsys insulin assay: free insulin determination and the absence of cross-reactivity with insulin lispro. Clin Chem 2001; 47: 602-605.
33. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
34. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410.
35. Shortman K, Williams N, Adams P. The separation of different cell classes from lymphoid organs. V. Simple procedures for the removal of cell debris. Damaged cells and erythroid cells from lymphoid cell suspensions. J Immunol Methods 1972; 1: 273-287.
36. Harada H, Asano O, Hoshino Y, et al. 2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A2B receptor. J Med Chem 2001; 44: 170-179.
37. San Martín R, Sobrevia L. Gestational diabetes and the adenosine/L-arginine/nitric oxide (ALANO) pathway in human umbilical vein endothelium. Placenta 2006; 27: 1-10.
38. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 813-823.
39. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity induced insulin resistance in mice lacking TNF-α function. Nature 1997; 389: 610-614.
40. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006; 24: 99-146.
41. Markel G, Wolf D, Hanna J, et al. Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest 2002; 110: 943-953.
42. Pfeiffer A, Middelberg-Bisping K, Drewes C, Schatz H. Elevated plasma levels of transforming growth factor-beta 1 in NIDDM. Diabetes Care 1996; 19: 1113-1117.
43. Azar ST, Salti I, Zantout MS, Major S. Alterations in plasma transforming growth factor beta in normoalbuminuric type 1 and type 2 diabetic patients. J Clin Endocrinol Metab 2000; 85: 4680-4682.
44. Diaz-Flores M, Ibanez-Hernandez MA, Galvan RE, et al. Glucose-6-phosphate dehydrogenase activity and NADPH/NADP1 ratio in liver and pancreas are dependent on the severity of hyperglycemia in rat. Life Sci 2006; 78: 2601-2607.
45. Xu Y, Osborne BW, Stanton RC. Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of protein kinase A which contributes to oxidative stress in rat kidney cortex. Am J Physiol Renal Physiol 2005; 289: F1040-F1047.
46. Zhang Z, Apse KJP, Stanton RC. High glucose inhibits glucose 6-phosphate dehydrogenase via cAMP in aortic endothelial cells. J Biol Chem 2000; 275: 40042-40047.
47. Ndisang JF. Role of heme oxygenase in inflammation, insulin-signalling, diabetes and obesity. Mediators Inflamm 2010; 2010: 359732.
48. Pácal L, Varvařovská J, Rušavý Z, et al. Parameters of oxidative stress, DNA damage and DNA repair in type 1 and type 2 diabetes mellitus. Arch Physiol Biochem 2011; 117: 222-230.
49. Blasiak J, Arabski M, Krupa R, et al. DNA damage and repair in type 2 diabetes mellitus. Mutat Res 2004; 554: 297-304.
50. Chaussade C, Rewcastle GW, Kendall JD, et al. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J 2007; 404: 449-458.
51. Vanhaesebroeck B, Welham MJ, Kotani K, et al. p110δ, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A 1997; 94: 4330-4335.
52. Patterson KI, Brummer T, O'Brien PM, Daly RJ. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 2009; 418: 475-489.
53. Berasi SP, Huard C, Li D, et al. Inhibition of gluconeogenesis through transcriptional activation of EGR1 and DUSP4 by AMP-activated kinase. J Biol Chem 2006; 281: 27167-27177.
54. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1: 15-25.
55. Andreelli F, Foretz M, Knauf C, et al. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 2006; 147: 2432-2441.
56. Jewell JL, Oh E, Thurmond DC. Exocytosis mechanisms underlying insulin release and glucose uptake: conserved roles for Munc18c and syntaxin 4. Am J Physiol Regul Integr Comp Physiol 2010; 298: R517-R531.
57. Gleason CE, Ning Y, Cominski TP, et al. Role of insulin-like growth factor-binding protein 5 (IGFBP5) in organismal and pancreatic beta-cell growth. Mol Endocrinol 2010; 24: 178-192.
58. Giannini S, Cresci B, Pala L, et al. IGFBPs modulate IGF-I- and high glucose-controlled growth of human retinal endothelial cells. J Endocrinol 2001; 171: 273-284.
59. Jehle PM, Jehle DR, Mohan S, Böhm BO. Serum levels of insulin-like growth factor system components and relationship to bone metabolism in type 1 and type 2 diabetes mellitus patients. J Endocrinol 1998; 159: 297-306.
60. Qiao L, MacLean PS, You H, Schaack J, Shao J. Knocking down liver CCAAT/enhancer-binding protein alpha by adenovirus-transduced silent interfering ribonucleic acid improves hepatic gluconeogenesis and lipid homeostasis in db/db mice. Endocrinology 2006; 147: 3060-3069.
61. Xie X, Liao H, Dang H, et al. Down-regulation of hepatic HNF4alpha gene expression during hyperinsulinemia via SREBPs. Mol Endocrinol 2009; 23: 434-443.
62. Bayraktutan U. Free radicals, diabetes and endothelial dysfunction. Diabetes Obes Metab 2002; 4: 224-238.
63. Pandolfi A, Di Pietro N. High glucose, nitric oxide, and adenosine: a vicious circle in chronic hyperglycaemia? Cardiovasc Res 2010; 86: 9-11.
64. Baker DJ, Greenhaff PL, Timmons JA. Glycogen phosphorylase inhibition as a therapeutic target: a review of the recent patent literature. Expert Opin Ther Pat 2006; 16: 459-466.